Maxim Group Maintains INmune Bio(INMB.US) With Buy Rating, Maintains Target Price $22
Maxim Group Maintains INmune Bio(INMB.US) With Buy Rating, Maintains Target Price $22
Inmune Bio's Promising Pipeline and Financial Stability Justify Buy Rating
BTIG Maintains INmune Bio(INMB.US) With Buy Rating, Maintains Target Price $21
Scotiabank Maintains INmune Bio(INMB.US) With Buy Rating, Maintains Target Price $22
A. G. P. Initiates INmune Bio(INMB.US) With Buy Rating, Announces Target Price $20
Scotiabank Maintains INmune Bio(INMB.US) With Buy Rating, Maintains Target Price $22
Inmune Bio (INMB) Receives a Buy From Scotiabank
INmune Bio Initiated at Outperform by Raymond James
INmune Bio Analyst Ratings
Maxim Group Maintains INmune Bio(INMB.US) With Buy Rating, Maintains Target Price $22
BTIG Maintains INmune Bio(INMB.US) With Buy Rating, Maintains Target Price $21
Buy Rating Affirmed for Inmune Bio on Promising Clinical Data and Market Potential
Raymond James Initiates INmune Bio(INMB.US) With Buy Rating, Announces Target Price $18
Maxim Group Maintains INmune Bio(INMB.US) With Buy Rating, Maintains Target Price $22
Scotiabank Maintains INmune Bio(INMB.US) With Buy Rating, Maintains Target Price $22
Analysts Offer Insights on Healthcare Companies: Inmune Bio (INMB) and Zevra Therapeutics (ZVRA)
BTIG Maintains INmune Bio(INMB.US) With Buy Rating, Maintains Target Price $21
Inmune Bio's Promising AD Treatment Approach Merits Buy Rating, Analyst Says
Scotiabank Initiates Coverage On INmune Bio With Sector Outperform Rating, Announces Price Target of $22